Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 7/20 | 0.44 |
| ▸ | KCNJ5 | P48544 | 7/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 7/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185815 | 0.88 | KCNJ6 (0.57) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL3388865 | 0.84 | MAPK14 (0.52) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL3178328 | 0.82 | CDK8 (0.49) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL4421073 | 0.82 | CARM1 (0.43) | KCNJ6KCNJ5KCNJ3MAPK14TNF | |
| SCHEMBL4470729 | 0.77 | KCNJ6 (0.43) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL3174513 | 0.76 | KCNJ6 (0.43) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL3389842 | 0.76 | KCNJ6 (0.51) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL378881 | 0.70 | CDK8 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3176730 | 0.70 | CDK8 (0.46) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3165072 | 0.70 | CDK8 (0.45) | MAPK14MAPK13MAPK12MAPK11SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943243-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7652015-B2 | Suppression cytokines , tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080269244-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269244-A1 | Kinase Inhibitors | MAP3K1, MAP3K20, MAP3K19 | KCNJ6 673/4885KCNJ5 628/4885KCNJ3 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.